

Table S1 Mortality case of COVID-19 infection in patients with NSCLC

Case	Disease status	COVID-19 diagnosis date	COVID-19 vacciN/Ation	Current treatment	Current systemic treatment response	Lung RT	ECOG before COVID-19 infection	Smoking history	Age (years)/sex	Underlying lung disease	Time from COVID-19 infection to death (days)
1	NED after surgery	2022-03-11	N/A	Supportive care	N/A	No	2	Ex-smoker	92/M	COPD	7
2	NED after surgery	2022-03-28	N/A	N/A	N/A	No	1	Ex-smoker	82/M	IPF	5
3	NED after surgery	2022-03-06	Yes	Supportive care	PR	No	1	Ex-smoker	66/M	None	128
4	SD after lung RT	2022-03-21	N/A	Supportive care	PR	Yes	1	Current smoker	87/M	None	3
5	SD after lung RT	2022-03-21	No	Supportive care	PR	Yes	1	Ex-smoker	83/M	COPD	7
6	Locally advanced NSCLC	2021-11-12	N/A	Definitive CCRT	PR	Yes	1	Never-smoker	82/M	None	51
7	Locally advanced NSCLC	2022-04-13	Yes	Clinical trial	PD	No	2	Ex-smoker	74/M	None	88
8	Locally advanced NSCLC	2022-02-24	N/A	Definitive CCRT	PR	Yes	1	Ex-smoker	74/M	IPF	5
9	Locally advanced NSCLC	2022-02-23	Yes	Definitive CCRT	PR	Yes	1	Current smoker	72/M	IPF	7
10	Advanced NSCLC	2022-02-28	N/A	Osimertinib	SD	No	3	Never-smoker	90/F	None	3
11	Advanced NSCLC	2022-04-12	N/A	Definitive RT	N/A	Yes	1	Ex-smoker	84/M	None	1
12	Advanced NSCLC	2022-03-15	N/A	Alimta/carboplatin	PD	No	1	Ex-smoker	84/M	None	28
13	Advanced NSCLC	2022-03-03	N/A	Afatinib	PR	No	1	Current smoker	84/M	None	35
14	Advanced NSCLC	2022-03-15	Yes	Gefitinib	PD	No	1	Never-smoker	82/F	None	70
15	Advanced NSCLC	2022-03-10	No	Alimta/carboplatin	SD	No	2	Ex-smoker	81/M	None	1
16	Advanced NSCLC	2022-04-25	Yes	Alimta/cisplatin	PD	No	2	Ex-smoker	80/M	IPF	2
17	Advanced NSCLC	2022-03-29	Yes	Definitive CCRT	PR	Yes	1	Ex-smoker	80/M	None	139
18	Advanced NSCLC	2022-03-31	Yes	Alimta + carboplatin + pembrolizumab	PR	No	1	Never-smoker	79/M	None	40
19	Advanced NSCLC	2022-03-24	Yes	Definitive CCRT	PR	Yes	1	Ex-smoker	79/M	COPD	141
20	Advanced NSCLC	2022-01-23	Yes	Supportive care	PR	Yes	0	Ex-smoker	78/M	IPF	18
21	Advanced NSCLC	2022-03-07	Yes	Definitive CCRT	N/A	Yes	1	Ex-smoker	78/M	IPF	99
22	Advanced NSCLC	2022-03-22	Yes	RT alone	N/A	Yes	1	Current smoker	78/F	COPD	19
23	Advanced NSCLC	2022-04-03	Yes	Etoposide/ cisplatin	N/A	No	1	Current smoker	77/M	None	21
24	Advanced NSCLC	2022-02-28	Yes	Definitive CCRT	N/A	Yes	1	Ex-smoker	76/M	COPD	1
25	Advanced NSCLC	2022-02-24	N/A	Definitive CCRT	N/A	Yes	1	Ex-smoker	75/M	IPF	1
26	Advanced NSCLC	2022-04-12	Yes	Irinotecan	PD	Yes	2	Ex-smoker	74/M	None	76
27	Advanced NSCLC	2022-02-28	No	Vinorelbine	PD	No	1	Never-smoker	74/F	None	10
28	Advanced NSCLC	2022-02-28	N/A	Docetaxel	PR	No	3	Never-smoker	74/M	None	55
29	Advanced NSCLC	2022-02-23	Yes	Definitive CCRT	PR	Yes	1	Current smoker	73/M	IPF	7
30	Advanced NSCLC	2022-02-28	No	Vinorelbine	PD	No	1	Never-smoker	73/F	None	1
31	Advanced NSCLC	2022-02-16	Yes	Docetaxel	PD	No	2	Ex-smoker	72/M	None	13
32	Advanced NSCLC	2022-04-05	Yes	Definitive CCRT	N/A	yes	1	Ex-smoker	72/M	IPF	93
33	Advanced NSCLC	2022-03-15	N/A	Definitive CCRT	N/A	No	2	Ex-smoker	72/M	None	7
34	Advanced NSCLC	2022-04-11	N/A	Definitive CCRT	CR	Yes	1	Current smoker	71/M	ILD	76
35	Advanced NSCLC	2022-03-11	Yes	Definitive CCRT	N/A	Yes	1	Current smoker	71/M	None	33
36	Advanced NSCLC	2022-04-11	N/A	Docetaxel	SD	No	1	Never-smoker	70/M	None	21
37	Advanced NSCLC	2022-04-15	N/A	Definitive CCRT	SD	Yes	1	Never-smoker	70/M	COPD	6
38	Advanced NSCLC	2022-04-05	N/A	Alimta + carboplatin + pembrolizumab	PD	Yes	0	Current smoker	69/M	None	54
39	Advanced NSCLC	2022-03-12	N/A	Docetaxel	PR	Yes	2	Current smoker	69/M	COPD	50
40	Advanced NSCLC	2022-03-28	N/A	Paclitaxel/cisplatin	PR	Yes	1	Ex-smoker	68/M	None	9
41	Advanced NSCLC	2022-03-17	Yes	Durvalumab	PR	Yes	2	Current smoker	68/M	None	55
42	Advanced NSCLC	2022-02-23	N/A	Atezolizumab	SD	Yes	1	Ex-smoker	67/M	None	70
43	Advanced NSCLC	2022-03-07	Yes	Clinical trial	PD	Yes	1	Current smoker	67/M	None	43
44	Advanced NSCLC	2022-03-09	Yes	Docetaxel	PD	No	1	Current smoker	66/M	None	12
45	Advanced NSCLC	2022-02-18	N/A	Pembrolizumab	SD	Yes	1	Current smoker	66/M	None	182
46	Advanced NSCLC	2022-03-29	N/A	Gemcitabine/ carboplatin + pembrolizumab	N/A	No	0	Ex-smoker	63/M	None	53
47	Advanced NSCLC	2022-03-28	Yes	Alimta + carboplatin + pembrolizumab	N/A	No	0	Current smoker	61/M	None	11
48	Advanced NSCLC	2021-11-03	N/A	Pembrolizumab	N/A	Yes	2	Current smoker	60/F	None	210
49	Advanced NSCLC	2022-02-25	N/A	Docetaxel	SD	Yes	0	Never-smoker	59/F	None	9
50	Advanced NSCLC	2022-03-28	Yes	Gemcitabine/ carboplatin	SD	No	1	Never-smoker	52/F	None	79
51	Advanced NSCLC	2022-02-07	Yes	Docetaxel	SD	Yes	1	Current smoker	51/M	None	16
52	Advanced NSCLC	2022-02-28	Yes	Lorlatinib	PR	No	1	Current smoker	49/M	None	238
53	Advanced NSCLC	2022-04-05	N/A	Irinotecan/ cisplatin	SD	No	0	Current smoker	49/M	None	6
54	Advanced NSCLC	2022-04-13	N/A	Paclitaxel/ carboplatin	SD	Yes	1	Current smoker	46/M	None	73

COVID-19, coronavirus disease 2019; NSCLC, non-small-cell lung cancer; RT, radiotherapy; ECOG, European Cooperative Oncology Group; NED, no evidence of disease; N/A, not applicable; M, male; COPD, chronic obstructive pulmonary disease; IPF, idiopathic pulmonary fibrosis; CCRT, concurrent chemoradiotherapy; PR, partial response; SD, stable disease; PD, progressive disease; F, female.